186 related articles for article (PubMed ID: 23620486)
1. Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.
Ellens H; Deng S; Coleman J; Bentz J; Taub ME; Ragueneau-Majlessi I; Chung SP; Herédi-Szabó K; Neuhoff S; Palm J; Balimane P; Zhang L; Jamei M; Hanna I; O'Connor M; Bednarczyk D; Forsgard M; Chu X; Funk C; Guo A; Hillgren KM; Li L; Pak AY; Perloff ES; Rajaraman G; Salphati L; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yamagata T; Lee CA
Drug Metab Dispos; 2013 Jul; 41(7):1367-74. PubMed ID: 23620486
[TBL] [Abstract][Full Text] [Related]
2. Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.
Bentz J; O'Connor MP; Bednarczyk D; Coleman J; Lee C; Palm J; Pak YA; Perloff ES; Reyner E; Balimane P; Brännström M; Chu X; Funk C; Guo A; Hanna I; Herédi-Szabó K; Hillgren K; Li L; Hollnack-Pusch E; Jamei M; Lin X; Mason AK; Neuhoff S; Patel A; Podila L; Plise E; Rajaraman G; Salphati L; Sands E; Taub ME; Taur JS; Weitz D; Wortelboer HM; Xia CQ; Xiao G; Yabut J; Yamagata T; Zhang L; Ellens H
Drug Metab Dispos; 2013 Jul; 41(7):1347-66. PubMed ID: 23620485
[TBL] [Abstract][Full Text] [Related]
3. Selection of an Optimal In Vitro Model to Assess P-gp Inhibition: Comparison of Vesicular and Bidirectional Transcellular Transport Inhibition Assays.
Yabut J; Houle R; Wang S; Liaw A; Katwaru R; Collier H; Hittle L; Chu X
Drug Metab Dispos; 2022 Jul; 50(7):909-922. PubMed ID: 35489778
[TBL] [Abstract][Full Text] [Related]
4. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
Akamine Y; Yasui-Furukori N; Uno T
Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
[TBL] [Abstract][Full Text] [Related]
7. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage.
Sugimoto H; Matsumoto S; Tachibana M; Niwa S; Hirabayashi H; Amano N; Moriwaki T
J Pharm Sci; 2011 Sep; 100(9):4013-23. PubMed ID: 21678427
[TBL] [Abstract][Full Text] [Related]
8. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
9. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.
Cook JA; Feng B; Fenner KS; Kempshall S; Liu R; Rotter C; Smith DA; Troutman MD; Ullah M; Lee CA
Mol Pharm; 2010 Apr; 7(2):398-411. PubMed ID: 20025245
[TBL] [Abstract][Full Text] [Related]
10. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition.
Yamazaki S; Evers R; De Zwart L
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):55-67. PubMed ID: 34668334
[TBL] [Abstract][Full Text] [Related]
12. Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo.
Zhou T; Arya V; Zhang L
J Clin Pharmacol; 2019 Aug; 59(8):1049-1060. PubMed ID: 30924955
[TBL] [Abstract][Full Text] [Related]
13. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
14. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
15. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
16. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
17. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
19. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
Fenner KS; Troutman MD; Kempshall S; Cook JA; Ware JA; Smith DA; Lee CA
Clin Pharmacol Ther; 2009 Feb; 85(2):173-81. PubMed ID: 18987624
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
